Protocols Page ContentCurrent trialsTreatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate EraImplications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen Previous trialsNUCOG V3 vs 4 week GC as neoadjuvant treatment in muscle invasive bladder cancer.NUCOG VIChemotherapy after immunotherapy in patients with locally advanced and metastatic urothelial cancer – an observational, non-interventional study.VINGEMInclusion period: Q 3, 2013 – Q 1, 2018 Sites: Karolinska University Hospital, Sweden, Akerhus University Hospital, Norway, Rigshospitalet, DenmarkContact: Helle Pappot & Anders Ullén.VINSORInclusion period: Q3, 2011 – Q2, 2013 Sites: Karolinska University Hospital, Sweden, Rigshospitalet, Denmark, Aarhus University Hospital, Denmark.Contact: Anders Ullén, Helle Pappot & Mads Agerbæk.VINTREXInclusion period: Q3, 2014 – Q3, 2016Sites: Rigshospitalet, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital, all Denmark.Contact: Helle Pappot & Mads Agerbæk. Last updated: 29. January 2025 Responsible editor Webgruppen på Rigshospitalet Please give your consent in order to send your message. Please enter a valid email address. Note: This mail is not secure. Your email should therefore not include civil registration numbers or health information.Read how to send secure digital post:https://www.regionh.dk/securemail Write your message: Write your email (Must be filled out): If you wish to attach one or more files you will need to login first. Create account or log in I hereby give my consent to the Capital Region of Denmark to process the information in my enquiry for professional purposes only. Read the terms for your consent No e-mail has been registred for this user/group